Karyopharm Therapeutics Inc. (27)

Browse by Contract Category

Contracts

Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 24, 2021)
Form of Restricted Stock Unit Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
Form of Nonstatutory Stock Option Agreement for Inducement Grants adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Fifth Amendment to Lease, dated as of August 13, 2020, by and between the Registrant and AG-JCM Wells Avenue Property Owner, LLC (Filed With SEC on November 2, 2020)
Amendment to License Agreement, dated May 1, 2020, by and between Antengene Therapeutics Limited and the Registrant (Filed With SEC on August 4, 2020)
Form of Option Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
Letter Agreement, dated as of October 1, 2020, between the Registrant and Ran Frenkel (Filed With SEC on November 2, 2020)
Consulting Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)
Transition Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)
Letter Agreement, dated as of August 31, 2020, between the Company and Michael Mason (Filed With SEC on August 31, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Christopher B. Primiano (Filed With SEC on August 31, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Sharon Shacham, Ph.D., M.B.A (Filed With SEC on August 31, 2020)
Amended and Restated Letter Agreement, dated as of August 31, 2020, between the Company and Michael Kauffman, M.D., Ph.D (Filed With SEC on August 31, 2020)
Amendment No. 1 to the Open Market Sale Agreement, by and between the Company and Jefferies LLC, dated May 5, 2020 (Filed With SEC on May 5, 2020)
Underwriting Agreement, dated March 3, 2020, by and among the Company, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Jefferies LLC (Filed With SEC on March 4, 2020)
Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on February 26, 2020)
Revenue Interest Financing Agreement, dated September 14, 2019, between the Registrant and HealthCare Royalty Partners III, L.P, and HealthCare Royalty Partners IV, L.P (Filed With SEC on November 4, 2019)
Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on August 6, 2019)
Nonstatutory Stock Option Agreement, dated February 25, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)
Offer Letter, dated February 3, 2019, between the Company and Michael Mason (Filed With SEC on February 25, 2019)
Consulting Agreement dated January 18, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)
Retention Agreement dated January 17, 2019, between the Company and Cameron Peters (Filed With SEC on January 18, 2019)
Separation Agreement dated January 17, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)